Pharmaceuticals (Feb 2021)

Ameliorative Effects of Loganin on Arthritis in Chondrocytes and Destabilization of the Medial Meniscus-Induced Animal Model

  • Eunkuk Park,
  • Chang Gun Lee,
  • Seung Hee Yun,
  • Seokjin Hwang,
  • Hyoju Jeon,
  • Jeonghyun Kim,
  • Subin Yeo,
  • Hyesoo Jeong,
  • Seong-Hoon Yun,
  • Seon-Yong Jeong

DOI
https://doi.org/10.3390/ph14020135
Journal volume & issue
Vol. 14, no. 2
p. 135

Abstract

Read online

Arthritis is a common inflammatory disease that causes pain, stiffness, and joint swelling. Here, we investigated the ameliorative effects of loganin on arthritis in vitro and in vivo. A single bioactive compound was fractionated and isolated from Cornus officinalis (CO) extract to screen for anti-arthritic effects. A single component, loganin, was identified as a candidate. The CO extract and loganin inhibited the expression of factors associated with cartilage degradation, such as cyclooxygenase-2 (COX-2), matrix metalloproteinase 3 (MMP-3), and matrix metalloproteinase 13 (MMP-13), in interukin-1 beta (IL-1β)-induced chondrocyte inflammation. In addition, prostaglandin and collagenase levels were reduced following treatment of IL-1β-induced chondrocytes with loganin. In the destabilization of the medial meniscus (DMM)-induced mouse model, loganin administration attenuated cartilage degeneration by inhibiting COX-2, MMP-3, and MMP-13. Transverse micro-CT images revealed that loganin reduced DMM-induced osteophyte formation. These results indicate that loganin has protective effects in DMM-induced mice.

Keywords